303 related articles for article (PubMed ID: 8163696)
41. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
42. [Estrogen receptor studies in breast cancer based on histological material. Correlation with results from needle biopsy aspirates and pS2 protein determination].
Sauer T; Naess O
Tidsskr Nor Laegeforen; 1995 Sep; 115(23):2881-3. PubMed ID: 7570508
[TBL] [Abstract][Full Text] [Related]
43. Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas.
Sauer T; Naess O
Diagn Cytopathol; 1994; 11(2):165-7. PubMed ID: 7813365
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products.
Takahashi S; Narimatsu E; Asanuma H; Okazaki M; Okazaki A; Hirata K; Mori M; Chiba T; Sato N; Kikuchi K
Oncology; 1995; 52(5):371-5. PubMed ID: 7637953
[TBL] [Abstract][Full Text] [Related]
45. Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns.
Dookeran KA; Rye PD; Dearing SJ; Walker RA
J Pathol; 1993 Oct; 171(2):123-9. PubMed ID: 8283349
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
Effi AB; Aman NA; Koui BS; Koffi KD; Traoré ZC; Kouyate M
BMC Cancer; 2017 Feb; 17(1):115. PubMed ID: 28173783
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical study of hormone receptor and hormone-regulated protein expression in phyllodes tumour: comparison with fibroadenoma.
Umekita Y; Yoshida H
Virchows Arch; 1998 Oct; 433(4):311-4. PubMed ID: 9808432
[TBL] [Abstract][Full Text] [Related]
49. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
51. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.
Elledge RM; Ciocca DR; Langone G; McGuire WL
Cancer; 1993 Apr; 71(8):2499-506. PubMed ID: 8095853
[TBL] [Abstract][Full Text] [Related]
52. Oestrogen and progesterone receptor expression in mammary fibromatosis.
Rasbridge SA; Gillett CE; Millis RR
J Clin Pathol; 1993 Apr; 46(4):349-51. PubMed ID: 8496393
[TBL] [Abstract][Full Text] [Related]
53. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
[TBL] [Abstract][Full Text] [Related]
54. Estrogen & progesterone receptors measurement in breast cancer with enzyme-immunoassay & correlation with other prognostic factors.
Redkar AA; Kabre SS; Mittra I
Indian J Med Res; 1992 Feb; 96():1-8. PubMed ID: 1597324
[TBL] [Abstract][Full Text] [Related]
55. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
56. [Comparative analysis of various biochemical and immunohistochemical methods for evaluating hormone receptors in breast carcinoma].
Gallo C; Orlassino R; Demarchi A; Vallero P; Vineis C
Pathologica; 2002 Aug; 94(4):176-80. PubMed ID: 12325415
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours.
Pallud C; Le Doussal V; Pichon MF; Prud'homme JF; Hacene K; Milgrom E
Histopathology; 1993 Sep; 23(3):249-56. PubMed ID: 8225243
[TBL] [Abstract][Full Text] [Related]
58. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
[TBL] [Abstract][Full Text] [Related]
59. PS2 expression in BRCA1-associated breast cancers.
Charafe-Jauffre E; Eisinger F; Mathoulin-Portier MP; Sobol H; Jacquemier J
Anticancer Res; 2001; 21(4B):2877-81. PubMed ID: 11712780
[TBL] [Abstract][Full Text] [Related]
60. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
